Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Jiangsu Kanion Pharmaceutical Co's EV-to-EBIT or its related term are showing as below:
SHSE:600557'
s EV-to-EBIT Range Over the Past 10 Years
Min: 11.47 Med: 17.19 Max: 36.39
Current: 14.1
During the past 13 years, the highest EV-to-EBIT of Jiangsu Kanion Pharmaceutical Co was 36.39. The lowest was 11.47. And the median was 17.19.
SHSE:600557's EV-to-EBIT is ranked better than 55.41% of 684
companies
in the Drug Manufacturers industry
Industry Median: 15.655
vs SHSE:600557: 14.10
Jiangsu Kanion Pharmaceutical Co (SHSE:600557) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Jiangsu Kanion Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥4,903 Mil.
Jiangsu Kanion Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥366 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Kanion Pharmaceutical Co EV-to-EBIT Related Terms
Jiangsu Kanion Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Kanion Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Kanion Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Kanion Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Jiangsu Kanion Pharmaceutical Co's EV-to-EBIT falls into.
Jiangsu Kanion Pharmaceutical Co's current Enterprise Value is ¥5,163 Mil.
Jiangsu Kanion Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥366 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Kanion Pharmaceutical Co (SHSE:600557) has a EV-to-EBIT of 14.10 as of Sep. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jiangsu Kanion Pharmaceutical Co and its competitors. This is 18% below median its historical median of 17.19. Over the past decade, Jiangsu Kanion Pharmaceutical Co's EV-to-EBIT has ranged from 11.47 to 36.39. According to the industry distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #305 out of 684 companies in the Drug Manufacturers industry, placing it in the top 44.6%.
Is Jiangsu Kanion Pharmaceutical Co's EV-to-EBIT too high?
Jiangsu Kanion Pharmaceutical Co's current EV-to-EBIT of 14.10 is 18% below median its 10-year median of 17.19. Over the past 10 years, this metric has ranged from a low of 11.47 to a high of 36.39. The Drug Manufacturers industry median EV-to-EBIT is 15.66. Jiangsu Kanion Pharmaceutical Co's value of 14.10 is 9.9% below this industry median. Based on the distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #305 out of 684 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jiangsu Kanion Pharmaceutical Co has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Kanion Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Kanion Pharmaceutical Co ranks #305 out of 684 companies for EV-to-EBIT. This puts Jiangsu Kanion Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBIT is 15.66. Jiangsu Kanion Pharmaceutical Co's value of 14.10 is 9.9% below this benchmark. Historically, Jiangsu Kanion Pharmaceutical Co's own EV-to-EBIT has ranged from 11.47 to 36.39 over the past decade. While the company's 10-year median is 17.19 vs. the industry median of 15.66, Jiangsu Kanion Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.66, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Kanion Pharmaceutical Co's current EV-to-EBIT of 14.10 is 9.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Jiangsu Kanion Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Kanion Pharmaceutical Co's current EV-to-EBIT is 14.10, which is 18% below median its own 10-year median of 17.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Kanion Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Kanion Pharmaceutical Co (SHSE:600557) is currently considered Fairly Valued. The stock's GF Value™ is ¥13.35, compared to a current price of ¥12.23 — trading 8.4% below its estimated fair value. The current EV-to-EBIT is 14.10, which is 18% below median its 10-year median of 17.19 and 9.9% below the Drug Manufacturers industry median of 15.66. Jiangsu Kanion Pharmaceutical Co's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Jiangsu Kanion Pharmaceutical Co (SHSE:600557), the current EV-to-EBIT is 14.10 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Kanion Pharmaceutical Co (SHSE:600557) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Kanion Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥12.23 is trading 8.4% below its estimated GF Value™ of ¥13.35.
GuruFocus considers Jiangsu Kanion Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600557:
EV-to-EBIT: 14.10 (18% below median its 10-year median of 17.19)
GF Value™: ¥13.35 vs. price of ¥12.23 (8.4% below fair value)
Industry Position: 9.9% below the Drug Manufacturers median (#305 of 684)
No single metric tells the full story. See the SHSE:600557 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Kanion Pharmaceutical Co Ltd focuses on R&D, production and trade of traditional Chinese medicine. The company also makes orthopedics, cardiovascular, anti-infective and anti-tumor products.
87GF Score
Get the complete analysis for SHSE:600557
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600557 has been successfully added to your 
